Volume 20 (2021)
Volume 19 (2020)
Volume 18 (2019)
Volume 17 (2018)
Volume 16 (2017)
Volume 15 (2016)
Volume 14 (2015)
Volume 13 (2014)
Volume 12 (2013)
Volume 11 (2012)
Volume 10 (2011)
Original Article
1. Myasthenia gravis and coronavirus disease 2019: A report from Iran

Masoud Etemadifar; Mahsa Akafzadeh-Savari; Mehri Salari; Amirhossein Akhavan Sigari; Sara Ebrahimi-Pelarti; Nahad Sedaghat; Koorosh Etemad

Articles in Press, Corrected Proof, Available Online from 01 July 2021

Abstract
  Background: Coronavirus disease 2019 (COVID-19) is spreading rapidly and has affected millions of people worldwide. Comorbid diseases have complicated the course of infection and increased mortality. Myasthenia gravis (MG) affects the neuromuscular junctions (NMJs) and can compromise respiratory muscle ...  Read More

Original Article
2. Prevalence of coronavirus disease 2019 in patients with neuromyelitis optica in Isfahan, Iran, and a review on recent reports and literature

Masoud Etemadifar; Mehri Salari; Zahra Aminzade; Sara Ebrahimi; Sepand Tehrani-Fateh

Articles in Press, Accepted Manuscript, Available Online from 17 July 2021

Abstract
  Background: Despite many studies, it is still unclear how patients with neuromyelitis optica spectrum disorder (NMOSD) would respond to coronavirus disease 2019 (COVID-19). We conducted a research on prevalence of COVID-19 in patients with NMOSD in Isfahan, Iran. We have also reviewed the recent publications ...  Read More

Original Article
3. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: The first case-control blinded study

Fariborz Khorvash; Mohammad Javad Farajpour-Khanaposhtani; Helia Hemasian; Mohammad Saadatnia

Articles in Press, Accepted Manuscript, Available Online from 18 July 2021

Abstract
  Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated toward ...  Read More